kıbrıs ingiltere londra lefkoşa
DOLAR
35,1981
EURO
36,7471
STERLIN
44,2960
BITCOIN
$98.846
Adana Adıyaman Afyon Ağrı Aksaray Amasya Ankara Antalya Ardahan Artvin Aydın Balıkesir Bartın Batman Bayburt Bilecik Bingöl Bitlis Bolu Burdur Bursa Çanakkale Çankırı Çorum Denizli Diyarbakır Düzce Edirne Elazığ Erzincan Erzurum Eskişehir Gaziantep Giresun Gümüşhane Hakkari Hatay Iğdır Isparta İstanbul İzmir K.Maraş Karabük Karaman Kars Kastamonu Kayseri Kırıkkale Kırklareli Kırşehir Kilis Kocaeli Konya Kütahya Malatya Manisa Mardin Mersin Muğla Muş Nevşehir Niğde Ordu Osmaniye Rize Sakarya Samsun Siirt Sinop Sivas Şanlıurfa Şırnak Tekirdağ Tokat Trabzon Tunceli Uşak Van Yalova Yozgat Zonguldak
LONDRA
Hafif yağmur
7°C
LONDRA
7°C
Hafif yağmur
Pazar Rain and snow
6°C
Pazartesi Hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
10°C
Salı Kapalı
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
11°C
Çarşamba açık
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
11°C

Under 40s to be offered alternative to AstraZeneca vaccine

Under 40s to be offered alternative to AstraZeneca vaccine
07.05.2021
0
A+
A-

All under-40s are to be offered an alternative to the Oxford/AstraZeneca coronavirus vaccine as a precaution.

The advice from the Joint Committee on Vaccination and Immunisation marks an extension to existing guidance where those aged under 30 were given a choice of COVID-19 jab over blood clotting concerns.

The change comes despite the JCVI and the Medicines and Healthcare products Regulatory Agency (MHRA) saying there are no fresh safety concerns.

Previously, the MHRA had said the balance of risk for the AstraZeneca vaccine against COVID is very favourable for older people but “more finely balanced” for younger groups, who do not tend to suffer serious coronavirus illness.

It updates the UK guidance issued on 7 April that recommended people aged 18 to 29 should be offered the Pfizer or Moderna vaccines after data showed the AstraZeneca jab was linked to very rare blood clots.

Up to 28 April, the MHRA had received 242 reports of blood clots accompanied by low blood platelet count in the UK, all in people who had AstraZeneca, out of around 28.5 million doses given.

Of these cases there had been 49 deaths.

Regulators have said the benefits of the AstraZeneca vaccine continue to “outweigh the risks for the vast majority of adults”.

Yorumlar

Henüz yorum yapılmamış. İlk yorumu yukarıdaki form aracılığıyla siz yapabilirsiniz.